Barely Significant
← all excerpts

Evaluation of the Potential Benefits of Trimetazidine in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial.

Pharmaceuticals (Basel) · 2025 · PMC12472768 · PMID 41011150

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

borderline non-significantp > 0.05actually significant
Liver biochemical markers demonstrated comparability, with gamma-glutamyl transferase (GGT) and aspartate aminotransferase (AST) showing borderline non-significant differences (both p > 0.05), while alanine aminotransferase (ALT) revealed a significant difference ( p = 0.004).

also in 434 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.